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Introduction: Use of disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) may prevent
joint damage and potentially reduce joint replacement surgeries. We assessed the association between RA drug use
and joint replacement in Quebec, Canada.
Methods: A cohort of new-onset RA patients was identified from Quebec’s physician billing and hospitalization
databases from 2002–2011. The outcome was defined using procedure codes submitted by orthopedic surgeons.
Medication use was obtained from pharmacy databases. We used alternative Cox regression models with
time-dependent variables measuring the cumulative effects of past use during different time windows (one model
focussing on the first year after cohort entry) for methotrexate (MTX), and other DMARDs. Models were adjusted for
baseline sociodemographics, co-morbidity and prior health service use, time-dependent cumulative use of other drugs
(anti-tumor necrosis factor [anti-TNF] agents, other biologics, cyclooxygenase-2 inhibitors [COXIBs], nonselective
nonsteroidal antiinflammatory drugs [NSAIDs], and systemic steroids), and markers of disease severity.
Results: During follow-up, 608 joint replacements occurred among 11,333 patients (median follow-up: 4.6 years). The
best-fitting model relied on the cumulative early use (within the first year after cohort entry) of MTX and of other
DMARDs, with an interaction between MTX and other DMARDs. In this model, greater exposure within the first year,
to either MTX (adjusted hazard ratio, HR = 0.95 per 1 month, 95 % confidence interval, 95 % CI 0.93-0.97) or other
DMARDs (HR = 0.97, 95 % CI 0.95-0.99) was associated with longer time to joint replacement.
Conclusions: Our results suggest that longer exposure to either methotrexate (MTX) or other DMARDs within the first
year after RA diagnosis is associated with longer time to joint replacement surgery.Introduction
Rheumatoid arthritis (RA) is a serious inflammatory arth-
ritis and affects 1 % of the population in the developed
world [1]. RA is characterized by joint pain and swelling,
which may result in physical impairments, joint deformity,
disability, and decreased quality of life. The pain and loss* Correspondence: sasha.bernatsky@mcgill.ca
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controlled disease activity.
Treatment strategies for RA have improved dramatically
over the past decade. Furthermore, earlier treatment in-
creases the chance of clinical response and disease remis-
sion [2, 3] compared to the same treatment administered
later in the disease course [4]. Disease-modifying anti-
rheumatic drugs (DMARDs) include methotrexate (MTX),
which is widely considered the cornerstone in RA care.
Uncontrolled RA activity can lead to irreversible joint
damage requiring joint replacement surgery [5]. There areticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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suggesting that early and targeted treatment decreases
joint damage in RA. It is hoped that prompt initiation of
therapy and better control of disease could ultimately
decrease the long-term need for orthopedic surgery.
Population-based studies have demonstrated that ortho-
pedic surgery rates have declined alongside the concomi-
tant increase in anti-rheumatic drug use [6], however, it is
uncertain to what extent early therapy ultimately reduces
the need for later joint replacement surgery in RA.
In this study, we hypothesized that early drug exposure
soon after RA diagnosis reduces the risk of subsequent
joint replacement surgery. To assess this issue, we studied
the potential association between RA drug use and joint
replacement using a population-based RA cohort assem-
bled from health administrative databases in Quebec.
Methods
Data sources
We performed cohort analyses on new-onset RA patients
with public prescription drug coverage identified in the
Quebec Health Insurance Program (RAMQ) databases
from 2002–2011. In principle, as in each province in
Canada, all Quebec residents (approximately 7.6 million
persons) have access to comprehensive health care in
terms of physician visits and hospitalization. Adminis-
trative databases record hospitalization and physician
billing data for all residents of Quebec. The data include
hospitalization discharge diagnoses (a primary diagnosis
and up to 15 non-primary diagnoses per hospitalization,
abstracted by medical records clerks), and physician-visit
billing-claim diagnostic codes (a single diagnostic code is
allowed per visit). Those residents who are beneficiaries of
the provincial drug plan (which includes all seniors, and
any non-seniors without private drug insurance, repre-
senting approximately 40 % of residents) can also be
linked to the province’s dispensed prescription claims
database (which includes information about drug, dose,
duration, and dates).
We received ethics approval from the Quebec Com-
mission for Access to Information. All data were de-
nominalized, and identifying health card numbers were
scrambled by the Quebec Health Insurance Board. As the
data are anonymous, no informed consent is required
from individual patients.
Study population
To establish a population-based incident RA sample, all
physician visits with an RA diagnosis code between 1
January 2002 and 31 December 2011 were identified. To
increase the positive predictive value and specificity of the
RA case definition, cases required at least three visit bill-
ing codes using International Classification of Diseases
(ICD)-9, code 714 over a 3-year period, at least one ofwhich was by an internist or a rheumatologist. This repre-
sents an adaptation of the RA diagnosis that was recently
validated by Widdifield et al. (2013) using Ontario admin-
istrative data [7]. To identify truly incident (rather than
prevalent) RA cases, we removed any patient who had any
billing codes for RA prior to 1 January 2002, as data were
available from 1989. Patients were followed from cohort
entry (time when they fulfilled the RA case definition)
until their first joint replacement surgery, or were cen-
sored at death date, or the end of study period (31 Decem-
ber 2011), whichever came first. We restricted our
analyses to those patients who had drug coverage by the
public drug program at the cohort entry and during at
least 80 % of their follow-up time and who had follow up
longer than 1 year.
Exposure assessment
For each prescription of MTX, or other DMARDs (sulfa-
salazine, chloroquine, hydroxychloroquine, leflunomide,
cyclosporine, minocycline, penicillamine, and cyclophos-
phamide), anti-TNF inhibitors, other biologic DMARDs
(anakinra, rituximab, abatacept) cyclooxygenase-2 inhibi-
tors (COXIBs), nonselective nonsteroidal anti-inflammatory
drugs (NSAIDs) and systemic steroids, the start date, num-
ber of pills, dosage, and days supplied were retrieved from
the prescription claims and used to construct the daily drug
exposure matrix [8]. The daily exposure matrix was then
used to calculate time-dependent measures of cumulative
duration of use of a specific drug, or class of drugs until a
given day during the follow up [9]. For overlapping pre-
scriptions of the same drug, the individual was assumed to
have had prescriptions refilled early and completed the first
prescription before starting the second. The same rule was
applied to overlapping prescriptions of the same drug but
with different doses and overlapping prescriptions for dif-
ferent drugs within the same drug class (anti-TNF agents,
systemic steroids, COXIBs or NSAIDs). However, given
that combination use is common for DMARDs, prescrip-
tions for each class of DMARD were treated separately.
When there was a gap of 7 days or less between two pre-
scriptions of the same drug, or of different drugs within the
same drug class (excluding DMARDs), it was assumed that
the drug was taken continuously and the gap was filled with
the daily dose of the second prescription. Exposures to our
main anti-rheumatic drugs included 1) MTX and 2) other
DMARDs besides MTX.
Outcomes
The outcome of interest was the time from cohort entry
to the first joint replacement surgery (for any joint),
defined using the Canadian Classification of Health
Intervention (CCI) and the Canadian Classification of
Diagnostic, Therapeutic and Surgical Procedures (CCP)
procedure codes for joint replacement (see Appendix 1).
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Variables that were available in the administrative data-
bases and considered potential confounders for the associ-
ation between the drugs of interest and joint replacement
were selected a priori and adjusted for in all the multivari-
able models. These included sex, age at cohort entry (in
years and with a squared-age term added to account for
non-linear effects), place of residence (urban or rural, de-
fined from postal codes) social assistance status at cohort
entry, and ecological measures based on census data, on
income, education level, and employment rate in the area.
We used diagnostic codes from all outpatient physician
and/or hospital visits during the 3 years before cohort
entry to assess comorbidities (including osteoarthritis
(OA), myocardial infarction, diabetes, osteoporosis, cere-
brovascular disease, acute renal failure, chronic renal
failure, coronary artery disease, chronic obstructive pul-
monary disease (COPD), asthma, cancer and the Charlson
index). To discriminate between high and low users of the
health care system, we adjusted for a binary indicator of
high users, defined as people with at least 20 physician
visits in at least 1 year of the 3 years before baseline. To
adjust for disease severity, we used a time-varying variable
capturing the number of rheumatologist visits during the
follow-up period (log-transformed). We also controlled
for a time-varying indicator of the presence of extra-
articular manifestations of the disease during the follow
up; this included rheumatoid lung, Felty’s syndrome,
rheumatoid carditis, eye involvement, dermatological
complications (vasculitis, pyoderma gangrenosum), neu-
ropathies and amyloidosis. Finally, we adjusted for time-
dependent variables reflecting cumulative use of other
drugs, anti-TNF inhibitors, other biologics, COXIBs,
NSAIDs, and systemic steroids during the follow up, and
binary indicators of anti-TNF, MTX, other DMARDs,
COXIBs, NSAIDs, and systemic steroid use during the
period of 1 year before cohort entry.
Statistical analyses
Descriptive statistics were used to characterize the study
population. We used a Cox proportional hazards (PH) re-
gression model with time-dependent variables measuring
drug use for 1) MTX and 2) other DMARDs. As men-
tioned, the model also controlled for concomitant drug ex-
posure (anti-TNF inhibitors, other biologics, COXIBs,
NSAIDs, steroids). Our primary analyses considered the ef-
fects of early use of MTX and/or DMARDs, that is, in the
first year of follow up only. Different time windows for cu-
mulative drug use were considered in alternate models
[10]: 1) during the second year of follow up, 2) throughout
the entire follow up, and 3) throughout follow up but not
including the year prior to the index time for each event.
The cumulative use was obtained by summing the duration
of all prescriptions for the relevant drugs, up to a given dayover the relevant time period. We also tested for an inter-
action term between the cumulative effects of MTX and
other DMARDs to account for possibly increased or de-
creased risks among users of both drug classes. Adjusted
hazard ratios (HRs) with 95 % CIs were generated. The fit
to the data of the different models was compared with the
Akaike Information Criterion (AIC) [11].
In sensitivity analyses, we weighted the cumulative ex-
posure to evaluate if weighting past exposure by recent
use would improve the prediction of joint replacement
surgery [12]. This method estimates from the data the
relative weights of the timing of past exposure of each of
MTX and other DMARDs on risk of outcome. We also
performed sensitivity analysis excluding subjects with pre-
vious diagnosis of OA or excluding the cases of hip re-
placements, as these are less likely to be attributed to RA
in the early years. Finally in additional sensitivity analysis,
we used the propensity scores to adjust for potential dif-
ferences associated with the exposure of primary interest,
i.e., between the characteristics of patients who received
different treatments during the first year after the cohort
entry. To this end, we first used logistic regression to esti-
mate separate propensity scores (PS) for the first-year
treatment with 1) MTX and 2) other DMARDs. Both PS
estimated the probability of receiving the respective treat-
ment as a function of all time-fixed characteristics
available at the entry into the cohort. In two separate
analyses, we then included both PS in the multivariable
Cox models that also included the cumulative first-year
exposures to 1) MTX, 2) other DMARDs, and 3) their
interaction, and all time-dependent potential confounders.
The difference between the two PS-adjusted models was
that the first also included all time-fixed variables, while
the second excluded these time-fixed variables.
Results
We studied 11,365 incident RA patients who were
followed for at least 1 year. Baseline characteristics of the
RA patients are shown in Table 1. A majority (67.4 %)
were women, with a mean age of 65.3 (standard deviation
14.5) years at cohort entry.
A total of 608 joint replacements occurred during
55,780 person-years (median 4.6 years) of follow up, yield-
ing a rate of 1.09 joint replacements per 100 person-years.
The knee (41.6 %) and hip (28.2 %) were the most fre-
quent locations for joint replacement. During follow up,
10 % of the patients filled at least one prescription for
anti-TNF (ever-users), 58 % for MTX and 65 % had used
another DMARD.
Among the alternative measures of drug exposure, the
best-fitting multivariable Cox model relied on the cumula-
tive duration of drug use in the first year after cohort entry
(Table 2). Joint replacement throughout follow up was
significantly lower for patients with higher cumulative
Table 1 Baseline characteristics of the incident rheumatoid
arthritis cohort
Variable Number Percent or SD
Female 7,639 67.4
Age in years at cohort entry 65.3 14.5
Recipient of social assistance at cohort entrya 939 8.3
Urban residencea 8,884 78.4
High healthcare use at baseline 2981 26.3
Prior joint replacement 352 3.14
Comorbidities
Myocardial infarction 291 2.6
Diabetes 1,668 14.7
Osteoporosis 1,722 15.2
Cerebrovascular disease 54 0.48
Acute renal failure 314 2.8
Chronic renal failure 298 2.6
Coronary artery disease 1,952 17.2
COPD-asthma 2,587 22.8
Any type of cancer 1,326 11.7
Osteoarthritis 3,469 30.6
Charlson comorbidity 1.2 1.9




COPD chronic obstructive pulmonary disease, GC glucocorticoids, COXIBs
cyclooxygenase-2 inhibitors, NSAIDs nonselective nonsteroidal anti-inflammatory
drugs
aDefined by census tract data
Table 2 Best-fitting Cox regression model of time to joint
replacement surgery
Variable Hazard ratio 95 % CI
Age (at cohort entry) 1.19 1.10, 1.28
Age (at cohort entry) squared 1.00 1.00, 1.00
Female sex 0.80 0.66, 0.96
Recipient of social assistance at cohort entry 0.89 0.59, 1.35
Baseline urban residence 1.03 0.82, 1.28
Baseline regional employment ratea 1.00 0.98, 1.01
Baseline regional family incomea 1.00 0.99, 1.01
Baseline regional percent university graduatesa 1.00 0.99, 1.01
Extra-articular RA manifestations (time-dependent) 1.08 0.91, 1.28
Rheumatology visits at baseline (log-transformed) 1.24 1.11, 1.38
Rheumatology visits in follow up,
time dependent (log-transformed)
0.98 0.84, 1.15
High health care use at baseline 1.11 0.91, 1.35
Prior joint replacement 2.55 1.90, 3.43
Baseline comorbidities
Myocardial infarction 0.86 0.48, 1.56
Diabetes 0.99 0.76, 1.28
Osteoporosis 0.79 0.63, 0.99
Cerebrovascular disease 1.27 0.40, 4.02
Acute renal failure 1.16 0.68, 1.97
Chronic renal failure 1.60 0.90, 2.84
Coronary artery disease 1.01 0.81, 1.27
COPD-asthma 0.96 0.77, 1.18
Any type of cancer 1.01 0.72, 1.41
Osteoarthritis 2.15 1.81, 2.55
Charlson Comorbidity 0.92 0.85, 1.00
Drug use prior to cohort entry
Anti-TNF 1.00 0.35, 2.85
MTX 1.27 0.94, 1.70
Other DMARDs 1.13 0.88, 1.45
Systemic corticosteroids 1.15 0.97, 1.38
COXIBs 0.97 0.82, 1.15
NSAIDs 0.87 0.73, 1.03
Time-dependent cumulative drugs in
follow up (years)
Anti-TNF 1.13 0.99, 1.29
Other biologic drugs 1.37 0.61, 3.08
Systemic corticosteroids 1.01 0.94, 1.08
COXIBs 1.20 1.11, 1.30
NSAIDs 1.31 1.20, 1.43
Cumulative MTX in first year (months) 0.94 0.92, 0.96
Cumulative other DMARDs in first year months) 0.97 0.95, 0.99
RA rheumatoid arthritis, MTX methotrexate, DMARD disease-modifying
anti-rheumatic drug, COPD chronic obstructive pulmonary disease, TNF tumor
necrosis factor, COXIB cyclooxygenase-2 inhibitor, NSAID nonsteroidal
anti-inflammatory drug
aDefined by census tract data
Moura et al. Arthritis Research & Therapy  (2015) 17:197 Page 4 of 9duration of either MTX (HR = 0.95 per month of use, 95 %
CI 0.93, 0.97) or of other DMARDs (HR = 0.97 per month
of use, 95 % CI 0.95, 0.99) within the first year after cohort
entry. These results can respectively be translated into a
5 % decrease in the hazard of surgery associated with every
additional month of early MTX use in the first year of fol-
low up, and a 3 % decrease in the hazard of surgery for
every additional cumulative month of early use of other
DMARDs. These associations became much stronger with
prolonged use of the relevant drugs in the first year. For
example, the early use of MTX or other DMARDs for
6 months was associated with 31 % (HR = 0.69, 95 % CI
0.59, 0.80) and 27 % (HR = 0.83 95 % CI 0.73, 0.95) reduc-
tion in the hazard of joint replacement surgery during fol-
low up. To facilitate assessment of the impact of early
treatment with MTX and/or other DMARDs, Fig. 1 com-
pares the Kaplan-Meier-like curves, for the proportions of
patients who remain free of joint replacement in four sub-
groups, defined based on treatment(s) received during the
first year after the cohort entry: 1) users of MTX only
(Metho_only); 2) users of other DMARDs only































Fig. 1 Kaplan-Meier estimates of time to joint replacement surgery. Groups of drug exposure were based on treatment(s) received during the first
year after the cohort entry: 1) users of methotrexate (MTX) only (Metho_only); 2) users of other disease-modifying anti-rheumatic drugs (DMARD) only
(DMARDs_only); 3) users of both MTX and DMARDs (Metho_DMARDs); and 4) patients not prescribed either MTX or any other DMARD during the first
year of follow up (None)
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(Metho_DMARDs); and 4) patients not prescribed either
MTX or any other DMARDs during the first year of
follow up (None). It is evident that patients treated with
MTX and/or other DMARDs in the first year have lower
long-term risks of requiring joint replacement, with
cumulative risk during the first 4–8 years of follow up
lower by about 2 % (Fig. 1). For example, after about
6 years (2,000 days) the cumulative risk is about 5 % in
those treated versus about 7 % in those not treated in
the first year.
The model included an interaction between MTX and
other DMARDs: patients who used drugs in both classes
during the first year after cohort entry had a significantly
shorter time to joint replacement than those who used
only one of the two drug classes. We were unable to
estimate precisely the effect of cumulative duration of
anti-TNF agents during follow up (adjusted HR = 1.13 per
year of use, 95 % CI 0.99, 1.29) due to the small number
of anti-TNF users. Cumulative duration of NSAIDs and
COXIBs were associated with higher risk of joint replace-
ment (NSAIDs: HR = 1.31 per year of use, 95 % CI 1.20,
1.43; COXIBs: HR = 1.20 per year of use, 95 % CI 1.11,
1.30), as were a previous joint replacement (adjusted
HR = 2.55, 95 % CI 1.90, 3.43), rheumatology visit at base-
line (HR = 1.24, 95 % CI 1.11, 1.38) and diagnosis of OA
in the 3 years prior to RA onset (adjusted HR = 2.15, 95 %
CI 1.81, 2.55). The sensitivity analyses based on the novel,flexible weighted cumulative exposure model did not
improve our estimates of the long-term effects of RA
drug exposure. In sensitivity analysis, when we excluded
individuals with diagnosis of OA at baseline, the esti-
mates of the cumulative duration of MTX remained
similar to our main analysis (HR = 0.92 per month of
use, 95 % CI 0.89, 0.96). The effect of MTX was also
essentially unchanged by exclusion of the patients with
hip replacements (HR = 0.95, 95 % CI 0.91, 0.99).
However, in both sensitivity analyses, the confidence
interval was widened for the effect of other DMARDs.
In the PS-adjusted models, the estimated effects of both
main exposures, and of their interaction, were very
similar to the estimates from our multivariable model
(see Additional file 1).Discussion
In our sample of patients with new-onset RA, in-
creased duration of exposure to either MTX or other
DMARDs early after the cohort entry was associated
with significantly longer time to joint replacement.
This finding is consistent with other studies suggest-
ing that early use of DMARDs results in both short-
term and long-term benefits [13–16]. In a population-
based cohort study, patients treated early with
DMARDs (within the first year of symptom onset)
had a significantly lower progression rate in RA
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years after symptom onset [15]. Results from the
Utrecht Rheumatoid Arthritis Cohort showed that treat-
ment with conventional DMARDs immediately after diag-
nosis resulted in less joint surgery when compared with a
delayed start [16]. The rationale for a prompt initiation of
DMARDs in patients with RA is based on the idea that
there is a critical therapeutic window of opportunity, in
which disease modification is more successful, possibly
because the pathogenetic mechanisms are still in early
development [3]. Although biologic therapies were
introduced to the Quebec formulary in 2002, our study
was unable to make any definitive conclusions about a
potential association between these therapies and later
need for joint surgery. In the current dataset, very early
use (within the first year after RA onset) of biologics
was rare.
A caveat to our main findings is that among the co-
hort members with incident RA, about a quarter did
not receive any DMARD therapy during the follow-up
time (median of 4.5 years). These individuals tended
to be older, and to have more comorbidities at base-
line. This combination of increased age and comor-
bidity may represent a relative contraindication to
DMARD use in this subgroup. Conversely, they may
represent a subgroup with milder disease. We lack the
clinical data to make this determination. This group
also had a higher frequency of pre-existing OA and
joint replacement surgery even prior to the cohort
entry, and therefore would be expected to be at high
risk of requiring future joint surgery. This subset of
individuals not receiving MTX or other DMARDs, be-
ing at high risk of requiring future joint surgery for
OA, could explain part of the observed potentially pro-
tective effect of cumulative MTX and other DMARD use
in the first year of cohort entry. Although the primary indi-
cation for joint surgery could not be confirmed from the
data, we did seek to address this issue by adjusting for base-
line presence of OA and for current and past exposure to
NSAIDs and COXIBs.
In our study, patients who were concurrently or se-
quentially prescribed both MTX and other DMARDs
within the first year after cohort entry had a shorter
time to joint replacement, i.e., a higher risk of joint
replacement, than users of only one of these drug
classes. This perhaps reflects unmeasured confound-
ing by indication, if the use of combination DMARDs
is taken as a marker for patients with the most active
or severe disease, and accordingly those who are the
most susceptible to need early surgery. Confounding
by indication has been demonstrated in other obser-
vational RA cohorts, with appropriate adjustmentsmade during analysis [17, 18]. While administrative
data have the advantage of being population-based
and including large numbers of patients, such data
do not include the clinical parameters needed to
adjust for disease severity/potential confounding by
indication.
Given the observational nature of our study, our
results are also subject to other possible unmeasured
confounders and selection bias. For example, it is
possible that receiving either MTX alone or other
traditional DMARDs is a marker of unmeasured patient
characteristics that would influence willingness to re-
ceive joint replacement surgery. Other factors that may
be effect modifiers, such as smoking or body mass
index, were unavailable in our dataset, although it is un-
clear how important such variables might be for the
current analyses.
Our analyses complement the existing literature. A
few studies have investigated whether patients with
new-onset RA during the pre-biologic era were more
likely to need joint surgery later on, compared to pa-
tients with new-onset RA in more recent times (bio-
logics having being available in most developed nations
for over a decade) [19, 20]. One, based on chart review
in adults with new-onset RA in the US showed that for
the period 1980–1994, 12.1 % of patients had undergone
joint surgery 10 years after RA onset. In contrast, the
authors found that in a similar, more recent retrospect-
ive cohort of new-onset RA, followed from 1995–2007,
only 6.0 % had had joint surgery after 10 years. The au-
thors interpreted the lower joint replacement rate as in-
dicative of improved RA treatments [19]. Similar
conclusions were reached in a Finnish study [21]. Con-
versely, a multicenter study in Japan did not observe a
decrease in the rates of RA-associated orthopedic
surgery from 1998–2008, despite a steady increase in
the proportion of patients using biologics from 2004
(1.8 %) to 2007 (10.0 %) [22]. One possible explanation
for that finding is that in more recent years, patients
who seek greater levels of activity may be undergoing
joint surgery earlier than patients in the past. In
addition, the study from Japan included not just joint
replacements but also other types of surgery. Finally,
technological advancements mean that patients today
have more joint-preserving surgical options than in the
past.
The strengths of our study are its population-based
nature and the availability of detailed drug prescription
data. However, data from administrative sources lack
primary clinical information on important clinical char-
acteristics, which makes it difficult to adjust for RA se-
verity. Similar to other database studies of drugs use
List of CCI/CCP procedure codes for joint replacement
Canadian Classification of Health Interventions
Code Description
1EL53 Implantation of internal device, temporomandibular joint [TMJ]
1SQ53 Implantation of device, pelvis
1TA53 Implantation of internal device, shoulder joint
1TM53 Implantation of internal device, elbow joint
1UB53 Implantation of internal device, wrist joint
1UC53 Implantation of internal device, distal radioulnar joint and carpal
joints and bones
1UG53 Implantation of internal device, metacarpophalangeal joint(s)
1UH53 Implantation of internal device, first metacarpophalangeal joint
1UK53 Implantation of internal device, interphalangeal joints of hand
1UM53 Implantation of internal device, first interphalangeal joint
of hand
1VA53 Implantation of internal device, hip joint
1VG53 Implantation of internal device, knee joint
1VP53 Implantation of internal device, patella
1WA53 Implantation of internal device, ankle joint
1WE53 Implantation of internal device, tarsal bones and intertarsal
joints [hindfoot, midfoot]
1WI53 Implantation of internal device, first metatarsal bone and first
metatarsophalangeal joint
1WJ53 Implantation of internal device, tarsometatarsal joints,
metatarsal bones and metatatarsophalangeal joints [forefoot]
1WM53 Implantation of internal device, interphalangeal joints of toe
1WN53 Implantation of internal device, first interphalangeal joint of toe
Canadian Classification of Diagnostic, Therapeutic and Surgical
Procedures (CCP)
Code Description
9341 Total knee replacement (geomedic) (polyc
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RA severity, including extra-articular manifestations of
RA, number of rheumatology visits, and use of con-
comitant medications like glucocorticoids. This ap-
proach has been used by other authors and appears to
control to some extent for disease severity [25], though
it is not ideal.
Time until joint replacement, as measured in our
study, is influenced not only by necessity, but also by
healthcare access. For example, individuals with higher
socioeconomic status tend to have better access to care,
and thus, have shorter waiting times even within pub-
licly funded healthcare systems, to receive elective sur-
gery [26]. In our study, we adjusted for variables related
to socioeconomic status, such as being on social assist-
ance, and ecological measures such as family income,
employment, and education [27]. We were not able to
address other issues related to accessibility, such as wait
times to either consult a surgeon or obtain surgery or
difficulties on the part of patients to attend appoint-
ments. Finally, we have to take some aspects into ac-
count when extrapolating our results. The rate of
biologic use represents an average over time and ac-
counts for periods when these drugs were not yet widely
available. Nevertheless, the frequency of use of both
biologics and non-biologic DMARDs found in our study
is not greatly different from those documented in
similar studies using administrative databases [28].
Moreover, the access to anti-TNF agents in Canada is
comparable to that observed in countries with a
similar income, with the exception of the USA [29].
All things considered, we believe the results of this
study can be informative for other countries with
similar sociodemographics characteristics and health-
care access.9348 Total ankle replacement
9350 Total hip replacement
9351 Total hip replacement with methyl methacrylate
9359 Other total hip replacement
9360 Other arthroplasty of hip
9361 Replacement of head of femur with use of methyl methacrylate
9362 Other replacement of head of femur
9363 Replacement of acetabulum with use of methyl methacrylate
9364 Other replacement of acetabulum
9370 Arthroplasty of hand and finger
9371 Arthroplasty of hand and finger with synthetic prosthesis
9380 Arthroplasty of upper extremity, except hand
9381 Arthroplasty of shoulder with synthetic
9384 Arthroplasty of elbow with synthetic prosthesis
9386 Arthroplasty of carpals with synthetic prosthesisConclusions
In summary, our study suggests that higher cumula-
tive use of MTX and higher cumulative use of non-
MTX traditional DMARDs within the first year after
the cohort entry may be associated with longer time
to joint surgery. A causal link cannot be firmly estab-
lished with these observational data; however, these
real-world findings may be consistent with joint-
sparing effects suggested by other data. Given that
biologic therapies were only recently introduced to
the Quebec formulary, our study was unable to make
any definitive conclusions about the potential effect of
these novel therapies and later need for surgery, but
analyses of future data using similar methods should
investigate this issue.Appendix 1
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Additional file 1: Propensity score analysis. Results of the propensity
score analysis for the main exposure drug groups and comparison with
the best-fitting multivariable Cox model. (DOC 39 kb)Abbreviations
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inhibitors; DMARDs: disease-modifying anti-rheumatic drugs; HR: hazard
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NSAIDs: nonselective nonsteroidal anti-inflammatory drugs; OA: osteoarthritis;
PH: proportional hazards; PS: propensity scores; RA: rheumatoid arthritis;
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